Kenneth Waggoner, outgoing PharmaCyte CEO
October 7, 2022 11:41 AM EDTUpdated 11:53 AM
People

Un­der the weight of a 2-year clin­i­cal hold, a biotech’s new board starts com­pa­ny re­view, ousts CEO

Kyle LaHucik

Senior Reporter

Af­ter near­ly 10 years steer­ing the ship at Phar­ma­Cyte Biotech, Ken­neth Wag­goner is out the door of the biotech, as of yes­ter­day, and the for­mer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

The drug lob­by's law­suit against the IRA finds a sign of life af­ter ap­peals court rul­ing

Biotech VC firm out­lines plans for $100M fund

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times